Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomi… Read more
Dr. Lal Path Labs Ltd. (LALPATHLAB) - Total Liabilities
Latest total liabilities as of September 2025: ₹5.37 Billion INR
Based on the latest financial reports, Dr. Lal Path Labs Ltd. (LALPATHLAB) has total liabilities worth ₹5.37 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Dr. Lal Path Labs Ltd. - Total Liabilities Trend (2011–2025)
This chart illustrates how Dr. Lal Path Labs Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Dr. Lal Path Labs Ltd. Competitors by Total Liabilities
The table below lists competitors of Dr. Lal Path Labs Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Watertek Information Technology Co Ltd
SHE:300324
|
China | CN¥2.68 Billion |
|
Thai Union Group Public Company Limited
PINK:THFRF
|
USA | $108.00 Billion |
|
Innovative Medical Management Co Ltd
SHE:002173
|
China | CN¥388.70 Million |
|
PTT OIL & RETAIL BUSINE-NVDR
BK:OR-R
|
Thailand | ฿95.42 Billion |
|
MFE MEDIAFOREUROPE NV
LSE:0NE1
|
UK | €3.61 Billion |
|
AnaptysBio Inc
NASDAQ:ANAB
|
USA | $327.19 Million |
|
Zhongshan Public Utilities Group Co Ltd
SHE:000685
|
China | CN¥17.17 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Dr. Lal Path Labs Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.88 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dr. Lal Path Labs Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dr. Lal Path Labs Ltd. (2011–2025)
The table below shows the annual total liabilities of Dr. Lal Path Labs Ltd. from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹5.10 Billion | -10.57% |
| 2024-03-31 | ₹5.71 Billion | -16.82% |
| 2023-03-31 | ₹6.86 Billion | -15.28% |
| 2022-03-31 | ₹8.10 Billion | +110.14% |
| 2021-03-31 | ₹3.85 Billion | +20.31% |
| 2020-03-31 | ₹3.20 Billion | +129.56% |
| 2019-03-31 | ₹1.40 Billion | +12.60% |
| 2018-03-31 | ₹1.24 Billion | +21.50% |
| 2017-03-31 | ₹1.02 Billion | -11.88% |
| 2016-03-31 | ₹1.16 Billion | -12.29% |
| 2015-03-31 | ₹1.32 Billion | +11.63% |
| 2014-03-31 | ₹1.18 Billion | +12.19% |
| 2013-03-31 | ₹1.05 Billion | +75.66% |
| 2012-03-31 | ₹599.73 Million | -21.25% |
| 2011-03-31 | ₹761.59 Million | -- |